Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Livmarli™ (maralixibat) – New orphan drug approval
September 29, 2021 - Mirum Pharmaceuticals announced the FDA approval of Livmarli (maralixibat), for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.
